SP-420 is under clinical development by Pharmacosmos and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SP-420’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SP-420 overview
SP-420 is under development for the treatment of transfusion dependent beta-thalassemia. The drug candidate is administered orally.
It was also under development for the treatment of , iron overload, Parkinson's Disease, age related macular degeneration, retinal degeneration, ischemia reperfusion, myelodysplastic (MDS) and myelofibrosis patients.
Pharmacosmos overview
Pharmacosmos is a pharmaceutical company. It specializes in carbohydrate chemistry and the development of treatments for blood diseases, particularly iron deficiency and anaemia. The company’s products include innovative treatments for iron deficiency and iron deficiency anaemia, as well as glucose poly- and oligosaccharides and their derivatives for pharmaceutical, high-tech, and medical use. Pharmacosmos also carries out veterinary medicine, producing ferric hydroxide complex for animal health. Its products serve patients suffering from iron-related conditions and are used in various medical and veterinary applications. The company operates in Denmark and the UK. Pharmacosmos is headquartered in Holbaek, Denmark.
For a complete picture of SP-420’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
